Area of research
Genetics · Molecular Biology
Research interest
Research interests include Cancer research, Biology, Cancer, CRISPR, Carcinogenesis, and Crizotinib.
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Rlf–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
DSpace@MIT (Massachusetts Institute of Technology) 2021cited by 43position: middle
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system